We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





World’s First Digital Human Organism Introduced at MEDICA 2021

By Dan Gueron, Publisher
Posted on 16 Nov 2021
Print article
Image: AIBODY platform (Photo courtesy of AIBODY.IO LTD.)
Image: AIBODY platform (Photo courtesy of AIBODY.IO LTD.)

AIBODY.IO LTD. (London, UK) unveiled the world's first complete digital human organism which can simulate virtually any medical condition or treatment at MEDICA 2021.

The AIBODY platform can produce true-to-life, highly detailed physiological responses to virtually any simulated medical condition or treatment protocol. Rather than rely on mathematical models to mimic aspects of human physiology, AIBODY’s virtual patient software is modeled from the sub-cellular level up and incorporates 132,000 parameters that interact to create lifelike simulations of interrelated biophysical, physiological, and biochemical processes occurring within a human body. AIBODY’s core product realistically replicates all concurrent cardiovascular, pulmonary, and bleeding processes, with other organ systems available soon.

AIBODY’s user-friendly interface, enhanced 3D graphics, and unlimited opportunities for customization and collaboration are revolutionizing medical education and training. The cloud-based AIBODY platform offers a dynamic virtual learning environment in which teams can diagnose and treat a broad range of medical conditions without risk to live patients or the need for physical presence. The AIBODY AR solution introduces sophisticated gesture controls and intuitive layouts that enable team-wide immersive experiences for multiple, geographically dispersed users collaborating on practical simulation exercises.

“Our medical simulation software lets us observe and treat a true-to-life digital patient – in real time and from anywhere in the world,” said AIBODY CEO Richard Littlehales. “It responds to injury and treatment exactly as a real human organism would, leading to myriad potential uses in medical education, professional certification training, bespoke simulations of medical procedures, and AR blended with haptics. In the future, we envision expanding the use of our platform to assist with clinical decision support, patient engagement, and pharmaceutical R&D and clinical trials.”

“COVID-19 has exposed systemic vulnerabilities in medical education and training that AIBODY is well positioned to solve,” added Littlehales. “Ours is the first platform to combine a unique human physiology engine with state-of-the-art visualization technologies, creating a product that requires minimal setup and enables the running of industry-leading simulations within minutes. Projects we are already working on include bringing textbooks to life through real-time patient simulation exercises that test students’ theoretical knowledge, and building customized ‘flight simulators’ for doctors and medical device developers to practice actual treatment routines.”

Related Links:
AIBODY.IO LTD.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Hospital Bed Mattress Cover
Skin IQ 365
New
Stereotactic QA Phantom
StereoPHAN

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.